One-carbon Therapeutics has inked a strategic collaboration with Tempus, a leader in AI‑enabled precision medicine, to advance the molecular understanding that will guide the clinical development of TH9619, its first‑in‑class inhibitor of MTHFD1/2.

 

The Swedish biotech will leverage Tempus’ extensive, de‑identified multimodal database and analytical expertise to map the expression landscape of one‑carbon metabolism across priority solid tumor types and understand how tumors rely on one‑carbon metabolism. These dependencies vary across indications and treatment settings, so it is essential to identify the patients most likely to benefit.

 

These analyses have the potential to sharpen clinical decision‑making, reduce development uncertainty and accelerate progress toward delivering innovative targeted therapies to people with advanced solid tumors.

 

Full details can be seen on the One-carbon Therapeutics website here.